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Summary Tumour S-phase fraction, but not the apoptotic fraction, had prognostic value in 92 patients with B-cell non-Hodgkin's lymphoma
(P< 0.0001 and P= 0.85 respectively). Multivariate analysis showed that S-phase fraction was the strongest prognostic indicator in all cases
(P = 0.0003, relative risk 4.3; age: P = 0.16; grade: P = 0.81), as well as in the 63 primary biopsy cases (P = 0.0006, relative risk = 7.3;
international prognostic index: P = 0.015, relative risk = 3.2; B symptoms: P= 0.017, relative risk = 3.3; bulkiness: P= 0. 65; grade: P= 0.91).
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The growth of tumours is expected to be dependent on the
'natural' rates ofapoptosis andproliferation, i.e. the rates observed
in the absence of clinical intervention. The survival of non-
Hodgkin's lymphoma (NHL) patients is dependent on successful
treatment, but survival may also depend on the growth of the
tumour before the initial diagnosis, or before relapse. A high frac-
tion of cells in S-phase correlated with poor prognosis in B-cell
NHL (Duque et al, 1993). Typically, there is a higher fraction of
cells in S-phase in high-grade NHL than in low-grade NHL
(Andreeffet al, 1986; Lenner et al, 1987; Christensson et al, 1989;
Rehn et al, 1990), which could mean that grade and S-phase frac-
tion do not have independent prognostic value. However, at least
some studies have shown that S-phase fraction is of prognostic
value even within the different histological subgroups
(Christensson etal, 1989; Rehn et al, 1990; Macartney etal, 1991).
The prognostic value ofapoptosis in NHL is not known.
Other parameters which have prognostic value in NHL include
WHO performance, serum lactate dehydrogenase (sLDH), stage,
number of extranodal sites and age. These parameters, based on
studies in high-grade NHL, have been combined into an 'intema-
tional prognostic index' (IPI; The International Non-Hodgkin's
Lymphoma Prognostic Factors Project, 1993). However, IPI also
has prognostic value in low-grade NHL (Hermans et al, 1995). We
report here that S-phase fraction is a strong prognostic parameter
in NHL, and that the apoptotic fraction has no prognostic value.
MATERIALS AND METHODS
The patients, as well as the method for assessment of the tumour-
specific apoptotic and S-phase fractions, are presented in Stokke et
al (1998). When previously treated, patients had been given either
CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone),
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CVP (cyclophosphamide, vincristine, prednisone) or chlor-
ambucil/prednisone with or without radiotherapy according to
standard protocols. The IPI was determined from WHO perfor-
mance (sLDH, stage, number of extranodal sites and age (The
International non-Hodgkin's Lymphoma Prognostic Factors
Project, 1993). Overall survival was calculated from the date of
the biopsy used for analysis until death from any cause. Patients
alive at the time of analysis were censored at their last follow-up
date. Cox proportional hazards multivariate regression analysis
(SPSS for Windows, SPSS Inc.) was performed to determine any
covariation and the associated risk of the factors, which were
found to have a P-value less than 0.20 by univariate analysis.
RESULTS
Since apoptosis andproliferation were notcorrelated (Stokke et al,
1998), these two parameters might have independent prognostic
value in NHL. Survival analysis was first performed for all the 92
patients for whom clinical data were available, i.e. including both
primary biopsies andbiopsies taken atrelapse/disease progression.
A cut-off at the median value (1.1%) was used for the apoptotic
fraction. The 'natural' apoptotic fraction was of no prognostic
value (P = 0.85; Table 1 andFigure lA), which was also the case if
the cut-off was set at 0.8%, 1.0%, 1.5%, 2.0%, 2.5% or 3.0%
(P > 0.7). The cut-off level for the S-phase fraction was deter-
mined directly from the log-transformed S-phase fraction
histogram as the value separating the two peaks (3%; Stokke et al,
1998). The prognostic value of the 'natural' S-phase fraction was
highly significant (Table 1 and Figure iB), which was also true if
the cut-offwas set at 2.0%, 2.5%, 3.5% or 4.0% (P < 0.0001 in all
cases). High tumour grade and age above 60 years were associated
with a poor prognosis. However, Cox proportional hazards simul-
taneous regression analysis showed that only the S-phase fraction
had independent prognostic value (Table 1). The prognostic value
ofgrade can be explained by the association with S-phase fraction,
but the latter has higher prognostic value.
The survival analysis wasperformed forpatients whohadreceived
differenttreatments. Wetherefore also studiedtheprognostic valueof
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Table 1 Statistical analysis of prognostic factors in NHL
All 92 cases 63 primary biopsy cases
Multivariate analysis Multivariate analysis
Univariate Univariate
Parameter P-value P-value RR 95% Cl P-value P-value RR 95% Cl
S-phase < 0.0001 0.0003 4.3 1.9-9.6 (61 < 3% vs. 31 > 3%) < 0.0001 0.0006 7.3 2.3-23 (39 < 3% vs. 24. 3%)
Apoptosis 0.85 (46 < 1.1% vs. 46. 1.1%) 0.75 (29 < 1.1% vs. 34. 1.1%)
Grade 0.0005 0.81 1.1 0.5-2.4 (63 low vs. 29 high) 0.0030 0.91 1.1 0.4-2.9 (41 low vs. 22 high)
Age 0.022 0.16 1.6 0.8-3.0 (59 < 60 vs. 33 > 60 years) 0.0055 (38 < 60 vs. 25 > 60 years)
sLDH 0.0004 (34 < 450 u 1-' vs. 28 > 450 1-1)
Stage 0.52 (121/ll vs. 51 III/IV)
WHO performance 0.0064 (59 0-1 vs. 42-4)
Extranodal 0.58 (470-1 vs. 16 .2)
IPI < 0.0001 0.015 3.2 1.3-8.1 (47 0-2 vs. 16 3-5)
Bulkiness 0.027 0.65 1.2 0.5-3.1 (39 < 6 cm vs. 24 > 6cm)
B symptoms 0.0005 0.017 3.3 1.2-8.9 (49 without vs. 14 with)
For P < 0.05, the adverse groups were: > 3% (S-phase); high (Grade); > 60 years (Age); > 450 i I-' (sLDH); 2-4 (WHO performance); 3-5 (IPI); > 6 cm
(Bulkiness); with (B symptoms) Cl, confidence interval; RR, relative risk.
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Figure 1 Overall survival of NHL patients. The survival of all 92 patients is shown for low (46 patients) and high (46 patients) apoptotic fraction (cut-off 1.1%)
(A) and low (61 patients) and high (31 patients) S-phase fraction (cut-off 3%) (B). The survival of the 63 primary biopsy patients is shown for low (39 patients)
and high (24 patients) S-phase fraction (cut-off 3%) (C), and for IPI 0-2 (47 patients) and 3-5 (16 patients) (D). Dotted lines and fully drawn lines show survival
for the low percentage or low IPI groups and the high percentage or high IPI groups respectively
S-phase fraction for patients who received a more aggressive doxo- phase < 3%, 17 cases with S phase 3%), as well as in the group of
rubicin-containing chemotherapy regimen (CHOP; 38 cases) and for patients who received milder chemotherapy (P < 0.0001; 28 cases
those who received milder forms ofchemotherapy (CVP orchloram- with S phase < 3%, 11 cases with S phase 3%).
bucil/prednisone; 39 cases). S-phase was of high prognostic signifi- Survival analysis was also performed for the 63 patients whose
cance in the aggressively treated group (P = 0.002; 21 cases with S biopsies were obtained at diagnosis, i.e. the primary biopsies. For
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these patients we had additional information about sLDH, stage,
WHO performance, number of extranodal sites, bulkiness of the
disease and B symptoms. In these cases, IPI could be derived. S-
phase fraction and IPI had thehighestprognostic valueby univariate
analysis in this group (Figure lC and D and Table 1). Apoptotic
fraction had no prognostic value. Multivariate analysis of the
presumably independent parameters, i.e. excluding the parameters
which make up IPI, showed that S-phase fraction, IPI and B symp-
toms had independent prognostic value (Table 1). S-phase fraction
was the strongest predictor of survival. If S-phase was not included
in the multivariate analysis, grade became significant (P = 0.02).
Twenty-seven of the 63 primary biopsy patients had received
CHOP, and 28 had received milder forms of chemotherapy. S-
phase was of prognostic significance in the CHOP-treated group
(P = 0.005; 14 cases with S phase < 3%, 13 cases with S phase
> 3%), as well as in the group of patients who had received
milder forms (P < 0.0001; 20 cases with S-phase < 3%, 8 cases
with S-phase > 3%).
DISCUSSION
The expected impact on tumour growth and the lack ofcorrelation
between apoptosis and proliferation suggested that these two para-
meters could have independent prognostic value in NHL. We
found no association between apoptotic fraction and survival. In
contrast to the 'natural' apoptotic fraction, the 'natural' S-phase
index is of high prognostic value whether assessed for all cases,
primary biopsies or rebiopsies. Our cut-off, determined directly
from the S-phase fraction distribution (Stokke et al, 1998), is lower
than the cut-offs used by most others (Lenner et al, 1987;
Christensson et al, 1989; Rehn et al, 1990; Macartney et al, 1991).
This is most likely related both to the high quality of the present
DNA distributions and to the gating procedure used to remove the
apoptotic cells before cell cycle analysis, resulting in a low back-
ground when determining the S-phase fraction. The prognostic
value of S-phase fraction could not be explained by differential
treatment ofpatients.
Multivariate analysis of the independence of the prognostic
value of the different parameters for all patients showed that only
S-phase had independent prognostic value, in contrast to grade and
age. Similarly, tumour S-phase fraction was the strongest prog-
nostic indicator for the primary biopsy cases. However, B symp-
toms and IPI also had independent prognostic value. Grade had
independent prognostic value only when S-phase fraction was
omitted from the multivariate analysis, showing that, although
grade correlates with S-phase fraction, the latter has a much higher
prognostic value and also carries all the prognostic value ofgrade.
In our sample, CHOP chemotherapy did not seem to improve the
survival of the patients with high S-phase fraction compared with
standard treatment with CVP orchlorambucil/prednisone (data not
shown). We therefore suggest that these high-risk patients should
be included in trials testing more aggressive therapy, e.g. high-
dose therapy with stem cell support.
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